Clinical and Translational Imaging

, Volume 6, Issue 6, pp 429–439 | Cite as

Radiopharmacology and molecular imaging of PD-L1 expression in cancer

  • Sofia Carrilho VazEmail author
  • Ana Sofia Capacho
  • Francisco P. Oliveira
  • Nuno Gil
  • Carla Teixeira Barros
  • António Parreira
  • Durval C. Costa
Systematic Review
Part of the following topical collections:
  1. Radiochemistry and radiopharmacology



Immunotherapy [(specifically, antibodies blocking programmed death ligand-1 (PD-L1)] is a valuable option in cancer treatment because it leads to durable tumour regression and improves survival in several cancers. Patients with PD-L1 expressing tumours benefit from this therapy, but currently it can only be determined through biopsy, which may be inconclusive or impossible due to lesion location, associated risks, intratumoral and interlesional heterogeneity. Therefore, radio-immune-imaging with a specific radiopharmaceutical is ideally placed to play an important role when performing real-time, in vivo, whole-body and non-invasive PD-L1 expression mapping.


To describe and summarise published scientific data on imaging PD-L1 expression using radiopharmaceuticals and discuss future directions in this research field.


A summary review of the literature was done through PubMed to search papers that described and included radiopharmaceuticals to image PD-L1 expression. Only English papers published until April 2018 that detailed laboratorial and animal procedures were selected.


Eleven pre-clinical papers published between 2015 and 2018 were included. Four studies used anti-PD-L1 radiopharmaceuticals labelled with Indium-111, 4 with Copper-64, 2 with Fluoride-18 and 1 with both Copper-64 and Gallium-68. All of them had identical protocols and showed similar radiopharmaceutical biodistribution. They reported successful anti-PD-L1 labelling, with high tumour–background ratio (mainly when spleen uptake was saturated with unlabelled/cold antibody).


All reported radiopharmaceuticals had high sensitivity and specificity to identify tumours with PD-L1 expression in animal model. Clinical experiments appear to be now justifiable.


Anti-PD-L1 Checkpoint inhibitors Immunotherapy Radiopharmacology Molecular imaging Nuclear medicine 


Author contributions

SCV: Literature Search and Review; Manuscript Writing, Editing and Content Planning. ASC: Literature Review; Manuscript Writing, Editing and Content Planning. FPO: Literature Review; Manuscript Writing, Editing and Content Planning. NG: Editing and Content Planning. CB: Editing and Content Planning. AP: Editing and Content Planning. DCC: Manuscript Writing, Editing and Content Planning.


S. C. Vaz, A. S. Capacho and D. C. Costa received antibody anti-PDL1 [clone 6E11] through a MTA from Genentech.

Compliance with ethical standards

Conflict of interest

F. P. Oliveira, N. Gil, C. Barros and A. Parreira declare no conflict of interest.

Ethical approval

Not applicable. This is a literature review. This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Not applicable.


  1. 1.
    Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG, Nimmagadda S (2016) A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7(9):10215–10227. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S (2016) PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET. Bioconjug Chem 27(9):2103–2110. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ehlerding EB, England CG, McNeel DG, Cai W (2016) Molecular imaging of immunotherapy targets in cancer. J Nucl Med 57(10):1487–1492. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384–3391. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10. CrossRefGoogle Scholar
  6. 6.
    Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y (2016) The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7(45):73068–73079. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Huang G, Sun X, Liu D, Zhang Y, Zhang B, Xiao G, Li X, Gao X, Hu C, Wang M, Ren H, Qin S (2017) The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget 9(3):4239–4248. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R (2015) Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 4(6):728–742. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7529):563–567. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365. CrossRefGoogle Scholar
  12. 12.
    Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM (2015) Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 112(47):E6506–E6514. CrossRefPubMedGoogle Scholar
  14. 14.
    Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G (2016) Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res 76(2):472–479. CrossRefPubMedGoogle Scholar
  15. 15.
    Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS (2015) Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem 26(10):2062–2069. CrossRefPubMedGoogle Scholar
  16. 16.
    Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS (2017) Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med 58(4):538–546. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Trotter DEG, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O’Malley SS, Lin S-A, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL (2017) In vivo imaging of the programmed death ligand 1 by 18F PET. J Nucl Med 58(11):1852–1857. CrossRefGoogle Scholar
  18. 18.
    Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, Morin PE, Huang RY-C, Chow PL, Hayes W Jr (2017) Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates. Bioorg Med Chem 25(20):5407–5414. CrossRefPubMedGoogle Scholar
  19. 19.
    England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W (2017) Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled Pembrolizumab. J Nucl Med 58(1):162–168. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mahmoudi M, Farokhzad OC (2017) Cancer immunotherapy: wound-bound checkpoint blockade. Nat Biomed Eng 1:0031. CrossRefGoogle Scholar
  21. 21.
    Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, S-l Teng, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558. CrossRefGoogle Scholar
  24. 24.
    Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G (2016) High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 6(10):1629–1640. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1231. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Heskamp S, Hobo W, Molkenboer-Kuenen JDM, Olive D, Oyen WJG, Dolstra H, Boerman OC (2015) Noninvasive imaging of tumor PD-L1 xxpression using radiolabeled anti-PD-L1 antibodies. Cancer Res 75(14):2928–2936. CrossRefPubMedGoogle Scholar
  27. 27.
    Kraeber-Bodere F, Bailly C, Chérel M, Chatal J-F (2016) ImmunoPET to help stratify patients for targeted therapies and to improve drug development. Eur J Nucl Med Mol Imaging 43(12):2166–2168. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Aguiar JPN, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes JGL (2017) The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol 28(9):2256–2263. CrossRefPubMedGoogle Scholar
  29. 29.
    Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, Lafont V, Tran T, Cole EL, Wright M, Kim J, Pena A, Kukral D, Dischino DD, Chow P, Gan J, Adelakun O, Wang X-T, Cao K, Leung D, Bonacorsi SJ, Hayes W (2018) Synthesis and biologic evaluation of a novel 18F-labeled adnectin as a PET radioligand for imaging PD-L1 expression. J Nucl Med 59(3):529–535. CrossRefPubMedGoogle Scholar
  30. 30.
    Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G (2017) Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. J Nucl Med 58(10):1560–1566. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Truillet C, Oh HLJ, Yeo SP, Lee C-Y, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang Y-H, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang C-I, Evans MJ (2018) Imaging PD-L1 expression with immunoPET. Bioconjug Chem 29(1):96–103. CrossRefPubMedGoogle Scholar
  32. 32.
    Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S (2017) Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochem Biophys Res Commun 483(1):258–263. CrossRefPubMedGoogle Scholar
  33. 33.
    Niemeijer A-LN, Smit EF, GaMSv Dongen, Windhorst AD, Huisman MC, Hendrikse NH, Leung DK, Smith RA, Hayes W, Velasquez LM, Bonacorsi SJ, Donnelly DJ, Morin PE, Thunnissen E, Poot AJ, Vugts DJ, Langen JD (2017) Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F-BMS-986192 in pts with NSCLC. J Clin Oncol 35(15_suppl):e20047. CrossRefGoogle Scholar
  34. 34.
    England CG, Rui L, Cai W (2017) Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging 44(3):517–532. CrossRefPubMedGoogle Scholar
  35. 35.
    Josefsson A, Nedrow J, Park S, Ranka S, Sgouros G (2016) Dosimetric analysis of Actinium-225 labeled anti-PD-L1 alpha particle radioimmunotherapy of melanoma cancer in an immunocompetent mouse model. J Nucl Med 57(Supplement 2):635Google Scholar
  36. 36.
    Kwak JJ, Tirumani SH, Abbeele ADVd, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35(2):424–437. CrossRefPubMedGoogle Scholar

Copyright information

© Italian Association of Nuclear Medicine and Molecular Imaging 2018

Authors and Affiliations

  1. 1.Champalimaud Foundation, Centre for the UnkownLisbonPortugal
  2. 2.Faculdade de Farmácia da Universidade de LisboaLisboaPortugal

Personalised recommendations